Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Collection of Additional Data Followed the Study "A Phase III Study of Velcade (Bortezomib) Thalidomide Dexaméthasone (VTD) Versus Velcade (Bortezomib) Cyclophosphamide Dexaméthasone (VCD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma"

NCT03089411 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT03089411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03089411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Collection of Additional Data Followed the Study "A Phase III Study of Velcade (Bortezomib) Thalidomide Dexaméthasone (VTD) Versus Velcade (Bortezomib) Cyclophosphamide Dexaméthasone (VCD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma"
Lead sponsor
Nantes University Hospital
Phase
Observational
Overall status
Unknown status
Start date
March 20, 2017
Completion date
July 15, 2017
Enrollment
340 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

myeloma multiple